ACS Pharmacol Transl Sci. 2026 Sep 17;9(10):3000-3004. doi: 10.1021/acsptsci.6c00552. eCollection 2026 Oct 9.
ABSTRACT
Dozens of agents that limit reperfusion injury preclinically have failed clinically. These failures are architectural, not biological: the right biology reaches the wrong place, as the wrong molecule, at the wrong time, judged by the wrong end point. We recast each as a design constraint and specify a staged regimen anchored at first medical contact.
PMID:42871611 | PMC:PMC13659830 | DOI:10.1021/acsptsci.6c00552